India & Sun Pharma
15 shared events · Importance 3 · Last updated Aug 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
India: India formulations sales grew 16% to Rs 5,475 crore, accounting for 36.1% of consolidated sales, and Sun Pharma maintained its position as the largest pharmaceutical company in India with market share rising to 8.5%.
Sun Pharma: Sun Pharma reported a 27% rise in Q1 net profit and 10.5% revenue growth, driven by India and innovative medicines, while US generics declined. The company is progressing on its Organon acquisition, expected to close in early 2027.
Jul 31, 2026 · 7 articles
Regulatory
India: India is the market where the recall occurred, affecting patients and distributors. The event highlights regulatory and safety concerns in the Indian pharmaceutical market, potentially prompting closer scrutiny of manufacturing practices.
Sun Pharma: Sun Pharma initiated the precautionary withdrawal of multiple eye drop products in India due to a contamination scare, instructing distributors to stop billing and return stocks. This action may lead to short-term revenue loss and reputational risk, but the company's emphasis on patient safety could help maintain trust.
Aug 01, 2026 · 7 articles
Regulatory
India: India was the first market where Sun Pharma received approval for generic semaglutide, serving as a precedent for this South African approval.
Sun Pharma: Sun Pharma received regulatory approval to market generic semaglutide in South Africa, its second market after India, enhancing its product portfolio and access to the diabetes treatment market.
Jul 15, 2026 · 8 articles
Regulatory
India: India is the country where the approval was granted; the decision addresses a significant public health burden of fatty liver disease.
Sun Pharma: Sun Pharma also offers generic semaglutide; the expanded Wegovy indication could affect its competitive position.
Jul 17, 2026 · 13 articles
Business
India: Domestic markets in India closed higher, supported by global cues, US labor data, and positive outcomes from the India-Japan Summit.
Sun Pharma: Sun Pharma was among the winning stocks, contributing to the overall market gains.
Jul 03, 2026 · 7 articles
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Sun Pharma: Sun Pharma is among the Indian generic drugmakers expected to introduce lower-priced versions of semaglutide after Semaglutide's patent expires.
Nov 11, 2025 · 6 articles
Domestic
India: Received upgraded growth forecast of 6.7% from RBI, reflecting resilient domestic economy despite global uncertainties.
Sun Pharma: Among laggards, possibly due to profit booking.
Aug 03, 2026 · 20 articles
International
Sun Pharma: Sun Pharma was among the firms that saw declines in the S&P BSE Sensex.
Jan 08, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Sun Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard